Contract Manufacturing, Gene Therapy and Immune Response

Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor

XTalks

FEBRUARY 27, 2024

Amtagvi must be administered at an authorized treatment center (ATC) as part of a treatment regimen that includes lymphodepletion and a short course of high-dose Proleukin (aldesleukin or human recombinant IL-2) to kickstart the immune response. Ziegler said it is on track to have more than 50 centers in about 100 days.

FDA Approval

FDA Approval Manufacturing In-Vivo Trials

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Manufacturing

Manufacturing Vaccine Vaccination Packaging

Clinical Research Informer

Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Webinars

Stay Connected